Sieve-Like CNT Film Coupled with TiO 2 Nanowire for High-Performance Continuous-Flow Photodegradation of Rhodamine B under Visible Light Irradiation
Abstract
Continuous-flow photoreactors hold great promise for the highly efficient photodegradation of pollutants due to their continuity and sustainability. However, how to enable a continuous-flow photoreactor with the combined features of high photodegradation efficiency and durability as well as broad-wavelength light absorption and large-scale processing remains a significant challenge. Herein, we demonstrate a facile and effective strategy to construct a sieve-like carbon nanotube (CNT)/TiO2 nanowire film (SCTF) with superior flexibility (180° bending), high tensile strength (75–82 MPa), good surface wettability, essential light penetration and convenient visible light absorption. Significantly, the unique architecture, featuring abundant, well-ordered and uniform mesopores with ca. 70 µm in diameter, as well as a homogenous distribution of TiO2 nanowires with an average diameter of ca. 500 nm, could act as a “waterway” for efficient solution infiltration through the SCTF, thereby, enabling the photocatalytic degradation of polluted water in a continuous-flow mode. The optimized SCTF-2.5 displayed favorable photocatalytic behavior with 96% degradation of rhodamine B (RhB) within 80 min and a rate constant of 0.0394 min−1. The continuous-flow photodegradation device made using SCTF-2.5 featured exceptional photocatalytic behavior for the continuous degradation of RhB under simulated solar irradiation with a high degradation ratio (99.6%) and long-term stability (99.2% retention after working continuously for 72 h). This work sheds light on new strategies for designing and fabricating high-performance continuous-flow photoreactors toward future uses.Citation
Nanomaterials, volume 11, issue 5, page e1335Publisher
MDPIType
articleDescription
From MDPI via Jisc Publications RouterHistory: accepted 2021-05-14, pub-electronic 2021-05-19
Publication status: Published
Funder: National Key Research and Development Program of China; Grant(s): 2016YFA0203301
Funder: National Natural Science Foundation of China; Grant(s): 51862035, 52062048
Funder: the Science and Technology Project of Jiangxi Province; Grant(s): 20192BCD40017, 20192ACB80002, S2018LQCQ0016, 2017-SJSYS-008
Collections
Related items
Showing items related by title, author, creator and subject.
-
Gene-Environment Interactions Relevant to Estrogen and Risk of Breast Cancer: Can Gene-Environment Interactions Be Detected Only among Candidate SNPs from Genome-Wide Association Studies?In this study we aim to examine gene–environment interactions (GxEs) between genes involved with estrogen metabolism and environmental factors related to estrogen exposure. GxE analyses were conducted with 1970 Korean breast cancer cases and 2052 controls in the case-control study, the Seoul Breast Cancer Study (SEBCS). A total of 11,555 SNPs from the 137 candidate genes were included in the GxE analyses with eight established environmental factors. A replication test was conducted by using an independent population from the Breast Cancer Association Consortium (BCAC), with 62,485 Europeans and 9047 Asians. The GxE tests were performed by using two-step methods in GxEScan software. Two interactions were found in the SEBCS. The first interaction was shown between rs13035764 of NCOA1 and age at menarche in the GE|2df model (p-2df = 1.2 × 10−3). The age at menarche before 14 years old was associated with the high risk of breast cancer, and the risk was higher when subjects had homozygous minor allele G. The second GxE was shown between rs851998 near ESR1 and height in the GE|2df model (p-2df = 1.1 × 10−4). Height taller than 160 cm was associated with a high risk of breast cancer, and the risk increased when the minor allele was added. The findings were not replicated in the BCAC. These results would suggest specificity in Koreans for breast cancer risk.
-
No Difference in Penetrance between Truncating and Missense/Aberrant Splicing Pathogenic Variants in MLH1 and MSH2: A Prospective Lynch Syndrome Database StudyBackground. Lynch syndrome is the most common genetic predisposition for hereditary cancer. Carriers of pathogenic changes in mismatch repair (MMR) genes have an increased risk of developing colorectal (CRC), endometrial, ovarian, urinary tract, prostate, and other cancers, depending on which gene is malfunctioning. In Lynch syndrome, differences in cancer incidence (penetrance) according to the gene involved have led to the stratification of cancer surveillance. By contrast, any differences in penetrance determined by the type of pathogenic variant remain unknown. Objective. To determine cumulative incidences of cancer in carriers of truncating and missense or aberrant splicing pathogenic variants of the MLH1 and MSH2 genes. Methods. Carriers of pathogenic variants of MLH1 (path_MLH1) and MSH2 (path_MSH2) genes filed in the Prospective Lynch Syndrome Database (PLSD) were categorized as truncating or missense/aberrant splicing according to the InSiGHT criteria for pathogenicity. Results. Among 5199 carriers, 1045 had missense or aberrant splicing variants, and 3930 had truncating variants. Prospective observation years for the two groups were 8205 and 34,141 years, respectively, after which there were no significant differences in incidences for cancer overall or for colorectal cancer or endometrial cancers separately. Conclusion. Truncating and missense or aberrant splicing pathogenic variants were associated with similar average cumulative incidences of cancer in carriers of path MLH1 and path_MSH2.
-
Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23Medulloblastoma is a rare brain malignancy. Patients after puberty are rare and bear an intermediate prognosis. Standard treatment consists of maximal resection plus radio-chemotherapy. Treatment toxicity is high and produces disabling long-term side effects. The sonic hedgehog (SHH) subgroup is highly overrepresented in the post-pubertal and adult population and can be targeted by smoothened (SMO) inhibitors. No practice-changing prospective randomized data have been generated in adults. The EORTC 1634-BTG/NOA-23 trial will randomize patients between standard-dose vs. reduced-dosed craniospinal radiotherapy and SHH-subgroup patients between the SMO inhibitor sonidegib (OdomzoTM, Sun Pharmaceuticals Industries, Inc., New York, USA) in addition to standard radio-chemotherapy vs. standard radio-chemotherapy alone to improve outcomes in view of decreased radiotherapy-related toxicity and increased efficacy. We will further investigate tumor tissue, blood, and cerebrospinal fluid as well as magnetic resonance imaging and radiotherapy plans to generate information that helps to further improve treatment outcomes. Given that treatment side effects typically occur late, long-term follow-up will monitor classic side effects of therapy, but also health-related quality of life, cognition, social and professional outcome, and reproduction and fertility. In summary, we will generate unprecedented data that will be translated into treatment changes in post-pubertal patients with medulloblastoma and will help to design future clinical trials.
